Dr. Usman's Cardiology Notes

  Malignant Arrhythmias: Recognition, Mechanisms, and Life-Saving Management --- What Are Malignant Arrhythmias? Malignant arrhythmias are life-threatening cardiac rhythm disturbances that can rapidly lead to hemodynamic collapse, cardiac arrest, and death if not treated immediately. They typically arise from ventricular myocardium and are characterized by instability and high mortality risk. --- Key Types of Malignant Arrhythmias 1. Ventricular Tachycardia (VT) Sustained VT (>30 seconds) or causing instability Monomorphic or polymorphic May present with palpitations, syncope, or shock 2. Ventricular Fibrillation (VF) Chaotic, disorganized ventricular activity No effective cardiac output Most common rhythm in sudden cardiac death 3. Torsades de Pointes Polymorphic VT associated with prolonged QT interval Characteristic “twisting of points” ECG pattern Often drug-induced or electrolyte-related 4. High-grade AV Block with Escape Failure Complete heart block with inadequate escape ...

Atrial Fibrillation and HFpEF: Diagnostic Challenges and Therapeutic Opportunities Introduction Atrial fibrillation (AF) and heart failure with preserved ejection fraction (HFpEF) frequently coexist, particularly in elderly patients with multiple comorbidities. Each condition can precipitate or exacerbate the other, creating a complex clinical syndrome associated with high morbidity, recurrent hospitalizations, and increased mortality. --- Pathophysiological Interplay AF and HFpEF share common risk factors: Hypertension Diabetes mellitus Obesity Aging Chronic kidney disease Key mechanisms linking AF and HFpEF: Left atrial (LA) remodeling: Elevated LV filling pressures → LA dilation → AF substrate Loss of atrial kick: Reduces LV filling → worsens HFpEF symptoms Tachycardia-induced cardiomyopathy: Persistent AF → diastolic dysfunction Fibrosis and inflammation: Shared substrate driving both conditions --- Diagnostic Challenges 1. Symptom Overlap Dyspnea, fatigue, and exercise intolerance...

Taming the Scar: Timing is the Therapy in Post-MI Healing Myocardial infarction (MI) sets off a tightly orchestrated healing response—where fibrosis is both protective and potentially harmful. A recent Cardiovascular Research study, highlighted by Prof. Isabel Goncalves, reframes this balance with a key insight: it’s not just the target, but the timing of intervention that determines outcomes. The Biological Paradox of Scar Formation After MI, cardiac fibroblasts transition into myofibroblasts, driving scar formation. This process is essential early on to prevent ventricular rupture—but excessive or persistent fibrosis leads to stiff myocardium, adverse remodeling, and heart failure. ADAM17 (a disintegrin and metalloproteinase-17) emerges as a central regulator in this process: Upregulated in infarcted myocardium Localized predominantly to activated myofibroblasts Linked to inflammation, growth factor signaling, and extracellular matrix remodeling  The Key Insight: Timing-Dependent...

Differences Between a Pseudoaneurysm and a True Aneurysm True Aneurysm A localized dilation of an artery involving all three layers of the vessel wall: intima, media, and adventitia. Pseudoaneurysm (False Aneurysm) A contained rupture of the arterial wall where blood leaks out and is held by surrounding tissues, not by the full vessel wall layers. --- Pathophysiology True Aneurysm Vessel wall weakens → gradual dilation Wall structure remains intact Common in chronic conditions Pseudoaneurysm Disruption of vessel wall → blood escapes Forms a pulsatile hematoma communicating with artery Wall is formed by fibrous tissue or surrounding structures --- Structural Difference Feature True Aneurysm Pseudoaneurysm Vessel wall layers All 3 layers intact Not intact Wall composition Native arterial wall Surrounding tissue / thrombus Neck Broad Narrow neck --- Common Causes True Aneurysm Atherosclerosis (most common) Hypertension Connective tissue disorders (e.g., Marfan syndrome) Degenerative chang...

  VT vs SVT With Aberrancy Brugada Algorithm Explained --- Introduction Wide complex tachycardia (WCT) is defined as a tachycardia with QRS duration ≥120 ms. The two most common causes are: • Ventricular Tachycardia (VT) • Supraventricular Tachycardia with Aberrancy (SVT-A) Distinguishing between them is critical because misdiagnosing VT as SVT can lead to inappropriate therapy and clinical deterioration. The Brugada Algorithm, introduced by Brugada et al. (1991), is one of the most widely used ECG methods to differentiate VT from SVT with aberrant conduction. --- Brugada Algorithm (Stepwise Approach) The algorithm consists of 4 sequential ECG questions. If the answer to any step is YES → Diagnose VT. If NO → Move to the next step. --- Step 1: Absence of RS Complex in All Precordial Leads Look at V1–V6. Check whether any lead has an RS complex. RS complex = an R wave followed by an S wave. If no RS complex is present in all precordial leads → VT This means the QRS complexes are eit...

Sacubitril/Valsartan Reduces Mortality More Than ACE Inhibitors in HFrEF Introduction Heart failure with reduced ejection fraction (HFrEF) remains a major cause of morbidity and mortality worldwide. For decades, ACE inhibitors were the cornerstone of therapy because they reduce mortality and hospitalization. However, the development of angiotensin receptor–neprilysin inhibitors (ARNIs), particularly sacubitril/valsartan, has significantly improved outcomes. Large randomized trials have demonstrated that sacubitril/valsartan reduces mortality and heart-failure hospitalizations more effectively than ACE inhibitors, leading to major changes in heart-failure guidelines. --- Mechanism of Action Sacubitril/valsartan combines two pharmacologic mechanisms: 1. Sacubitril (Neprilysin inhibitor) Inhibits neprilysin enzyme Prevents breakdown of natriuretic peptides Leads to: Vasodilation Natriuresis Reduced cardiac remodeling Decreased sympathetic activity 2. Valsartan (ARB) Blocks angiotensin II ...

SVT with Aberration SVT with aberration refers to a supraventricular tachycardia conducted through the ventricles with abnormal intraventricular conduction, resulting in a wide QRS complex (>120 ms) on ECG. Although the rhythm originates above the ventricles, conduction delay in the His–Purkinje system makes it appear similar to ventricular tachycardia. Correct identification is crucial because misdiagnosing SVT with aberrancy as VT (or vice versa) can lead to inappropriate management. --- Mechanisms Wide QRS during SVT occurs due to abnormalities in ventricular conduction. 1. Pre-existing Bundle Branch Block A patient with baseline right bundle branch block (RBBB) or left bundle branch block (LBBB) may develop SVT, which will naturally appear as a wide-complex tachycardia. 2. Rate-Dependent Aberrancy At very fast heart rates, one of the bundle branches may still be in its refractory period, leading to temporary conduction delay. This is commonly called functional bundle branch bloc...